Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- Human bone marrow progenitor cells: Potential relevance to remoxipride-induced aplastic anemia

Chemico-Biological Interactions

Volumn 121, Issue 3, 1999, Pages 253-265

  McGuinness, S M ^c   Johansson, R ^a   Lundstrom, J ^b   Ross, D ^c  

^a Preclinical R and D Astra Arcus AB ^*  (Sweden)

^b R and D Laboratories   (Sweden)

^c Box C238 Sch Pharm Univ C   (United States)

Author keywords

Aplastic anemia; Apoptosis; Benzene; Catechol; HL60 cells; Human bone marrow progenitor cells; Hydroquinone; Remoxipride

Indexed keywords

DNA FRAGMENT; DRUG METABOLITE; REMOXIPRIDE;

APLASTIC ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL STRAIN HL 60; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; STEM CELL;

ANEMIA, APLASTIC; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BENZENE; BENZIMIDAZOLES; CARCINOGENS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; REMOXIPRIDE;

EID: 0033063312     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00105-2     Document Type: Article

References (32)

1. Mohell N., Sallemark M., Rosqvist S., Malmberg A., Hogberg T., Jackson D.M. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur. J. Pharmacol. 238:1993;121-125.
2. Vartiainen H., Leinonen E., Putkonen A., Lang S., Hagert U., Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatr. Scand. 87:1993;114-117.
3. Eriksson L. Remoxipride in the treatment of psychoses. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;619-623.
4. Philpott N.J., Marsh J.C.W., Gordon-Smith E. Aplastic anaemia and remoxipride. Lancet. 342:1993;1244-1245.
5. Laidlaw S.T., Snowden J.A., Brown M.J. Communication. Lancet. 342:1998;1245-1245.
6. Kerwin R. Adverse reaction reporting and new antipsychotics. Lancet. 342:1993;1440.
7. Keks N., Burrows G.D. Withdrawal of remoxipride. Med. J. Austr. 160:1994;591.
8. Widman M., Nilsson L.B., Bryske B., Lundstrom J. Disposition of remoxipride in different species: species differences in metabolism. Arzneim. Forsch./Drug Res. 43:1993;287-297.
9. Smith M.T. Overview of benzene-induced aplastic anaemia. Eur. J. Haematol. (Suppl). 60:1996;107-110.
10. Levay G., Ross D., Bodell W.J. Peroxidase activation of hydroquinone results in the formation of DNA adducts in HL-60 cells, mouse bone marrow macrophages and human bone marrow. Carcinogenesis. 14(11):1993;2329-2334.
11. Zhang L., Wang Y., Sang N., Smith M.T. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes. Leuk. Res. 22(2):1998;105-113.
12. Stillman W.S., Varella-Garcia M., Gruntmeir J.J., Irons R.D. The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line. Leukemia. 11:1997;1540-1545.
13. Eastmond D.A., Smith M.T., Ruzo L.O., Ross D. Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase. Mol. Pharmacol. 30:1986;674-679.
14. Hedli C.C., Rao N.R., Reuhl K.R., Witmer C.M., Snyder R. Effects of benzene metabolite treatment on granulocytic differentiation and DNA adduct formation in HL-60 cells. Arch. Toxicol. 70:1996;135-144.
15. Yardley-Jones A., Anderson D., Parke D.V. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. Br. J. Ind. Med. 48:1991;437-444.
16. Hiraku Y., Kawanishi S. Oxidative DNA damage and apoptosis induced by benzene metabolites. Cancer Res. 56:1996;5172-5178.
17. Ross D., Beall H., Traver R.D., Siegel D., Phillips R.M., Gibson N.W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical and chemical studies. Oncol. Res. 6:1992;493-500.
18. Schattenberg D.G., Stillman W.S., Gruntmeir J.J., Helm K.M., Irons R.D., Ross D. Peroxidase activity in murine and human hematopoietic progenitor cells: potential relevance to benzene-induced toxicity. Mol. Pharmacol. 46:1994;346-351.
19. Ross D., Siegel D., Schattenberg D.G., Sun X.M., Moran J.L. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: identification of target cells and a potential role for modulation of apoptosis in benzene toxicity. Environ. Health Perspect. 104(6):1996;1177-1182.
20. Ross D. Metabolic basis of benzene toxicity. Eur. J. Haematol. (Suppl). 60:1996;111-118.
21. Young N.S., Maciejewski J. The pathophysiology of acquired aplastic anemia. N. Engl. J. Med. 336:1997;1365-1372.
22. Maciejewski J.P., Selleri C., Sata T., Anderson S., Young N.S. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Br. J. Haematol. 91:1995;245-252.
23. Philpott N.J., Scopes J., Marsh J.C.W., Gordon-Smith E.C., Gibson F.M. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp. Hematol. 23:1995;1642-1648.
24. Moran J.L., Siegel D., Sun X.-M., Ross D. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells. Mol. Pharmacol. 50:1996;610-615.
25. Kolachana P., Subrahmanyam V.V., Meyer K.B., Zhang L., Smith M.T. Benzene and its phenolic metabolites produce oxidative DNA damage in HL60 cells in vitro and in the bone marrow in vivo. Cancer Res. 53:1993;1023-1026.
26. Florvall L., Ogren S.-O. Potential neuroleptic agents: 2,6 dialkoxybenzamide derivatives with potent dopamine receptor blocking activities. J. Med. Chem. 25:1982;1280-1286.
27. Gawell L., Hagberg C.E., Hogberg T., Widman M. Synthesis of 5-substituted hydroxy-2-pyrrolidines, metabolites of the antipsychotic benzamide remoxipride. Acta Chem. Scand. 43:1989;476-480.
28. Nilsson L.B. Determination of remoxipride in plasma and urine by reversed-phase column chromatography. J. Chromatog. 526:1990;139-150.
29. Gerson W.T., Fine D.G., Spielberg S.P., Sensenbrenner L.L. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 61:1983;889-893.
30. Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol. Adverse Drug React. Ac. Pois. Rev. 5:1986;97-136.
31. Spielberg S.P. Pharmacogenetics and blood dyscrasias. Eur. J. Heamatol. 60:1996;93-97.
32. Nebert D.W., McKinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15:1996;273-280.